China SXT Pharmaceuticals (SXTC)
Manufacturer of Suxuantang traditional Chinese medicine pieces for Chinese hospitals, wholesalers and pharmacy chains.
Something off on this page? Send us feedback.
Manufactures and distributes Suxuantang-brand Traditional Chinese Medicine Pieces to hospitals, wholesalers and pharmacy chains in China, earning revenue at shipment or delivery. Regular decoction pieces supply most revenue, while a VIE structure links the listed BVI parent to its operating business.
Manufactures and distributes Traditional Chinese Medicine Pieces under the Suxuantang brand, with regular TCMP as its current revenue core and direct-use or after-soaking formats as a smaller offering. Products are sold to hospitals, pharmaceutical wholesalers and pharmacy chains in China, with end customers concentrated across several provinces.
Processes medicinal raw materials at its Taizhou facility and earns product-sale revenue at shipment or delivery. Applies modern processing and quality-control methods to its non-decocting formats, which offer administration convenience rather than a different medicinal effect. The listed BVI parent consolidates the revenue-producing operating entity through PRC contractual arrangements.
All operating assets and revenue are in China, and TCMP manufacturing depends on a Pharmaceutical Manufacturing Permit and GMP compliance.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $28.2M · Total debt $1.1M · Total assets $34.8M · Shareholders' equity $29.7M
- Revenue
- $1.2M
- Operating income
- −$784.0K
- Net income
- $163.7K
No dividends on record.
| Institutions3 holders · as of Mar 31, 2026 | 0.17% | 977 ADS | |
| Insiders1 holder · as of Apr 27, 2026 | — | 0 ADS |
institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Mar 2021 annual report; nothing newer is on file here.
No reliable share count is available for this listing, so stakes are shown as shares, not percentages.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
The institutional percentage is the one reported with the filings, not one recomputed on the share count here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Sabby Management, LLCInstitution | — | 78,170 ADS | 13Fas of Mar 31, 2026 |
Caitong International Asset Management Co., LtdInstitution | — | 1 ADS | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | — | 1 ADS | 13Fas of Mar 31, 2026 |
Feng Felix ZhouInsiderdirector, officer: Co-CEO and Director | — | 0 | Form 4filed Apr 27, 2026 ↗ |
Ayrton Capital LLCStrategic | —9.99% of class, as filed | — | 13G/Afiled Feb 14, 2020 ↗ |
| See all 12 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
Not reported.